Previous Article | Next Article 
Journal of Clinical Microbiology, September 1999, p. 2910-2912, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Polymorphism of the Human Immunodeficiency Virus
Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to
a Protease Inhibitor
Philippe
Bossi,1,2
Mireille
Mouroux,1
Anne
Yvon,1
François
Bricaire,2
Henri
Agut,1
Jean-Marie
Huraux,1
Christine
Katlama,2 and
Vincent
Calvez1,*
Departments of
Virology1 and Infectious
Diseases,2 Pitié-Salpêtrière
Hospital, Paris, France
Received 4 January 1999/Returned for modification 19 April
1999/Accepted 14 June 1999
In order to analyze the impact of protease gene polymorphism on
response to regimens containing a protease inhibitor, the entire
protease coding domain from 58 human immunodeficiency virus type 1 (HIV-1)-infected patients who were protease inhibitor naive was
sequenced before therapy was started. Plasma HIV-1 RNA levels were
measured at baseline and at month 3 and month 6 after treatment. All
patients were treated with a combination of two reverse transcriptase inhibitors and a protease inhibitor (saquinavir EOF
[n = 28], ritonavir [n = 16], or
indinavir [n = 14]). Before treatment, 30 different
positions whose codons differed from the subtype B consensus sequence
were observed. Major mutations associated with protease inhibitor
resistance were not observed. No statistical correlation between the
number of amino acid differences and the treatment efficacy at month 3 (
2.4 log) or month 6 (
2.7 log) was observed. At baseline, genotypic
analysis of the HIV-1 protease gene of patients who have never received
a protease inhibitor does not allow prediction of the efficacy of
regimens containing a protease inhibitor.
*
Corresponding author. Mailing address: Department of
Virology
CERVI, Hôpital Pitié-Salpêtrière,
47-83 Bd de l'Hôpital, 75651 Paris Cedex 13, France. Phone: 33 1 42 17 74 09. Fax: 33 1 42 17 74 11. E-mail:
vincent.calvez{at}psl.ap-hop-paris.fr.
Journal of Clinical Microbiology, September 1999, p. 2910-2912, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vega, Y., Perez-Alvarez, L., Delgado, E., Munoz, M., Casado, G., Carmona, R., Sierra, M., Vazquez de Parga, E., Pinilla, M., Garcia, V., Medrano, L., Contreras, G., Thomson, M., Najera, R.
(2005). Oligonucleotide Ligation Assay for Detection of Mutations Associated with Reverse Transcriptase and Protease Inhibitor Resistance in Non-B Subtypes and Recombinant Forms of Human Immunodeficiency Virus Type 1. J. Clin. Microbiol.
43: 5301-5304
[Abstract]
[Full Text]
-
Damond, F., Brun-Vezinet, F., Matheron, S., Peytavin, G., Campa, P., Pueyo, S., Mammano, F., Lastere, S., Farfara, I., Simon, F., Chene, G., Descamps, D.
(2005). Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors. J. Clin. Microbiol.
43: 484-487
[Abstract]
[Full Text]
-
Colson, P., Henry, M., Tourres, C., Lozachmeur, D., Gallais, H., Gastaut, J. A., Moreau, J., Tamalet, C.
(2004). Polymorphism and Drug-Selected Mutations in the Protease Gene of Human Immunodeficiency Virus Type 2 from Patients Living in Southern France. J. Clin. Microbiol.
42: 570-577
[Abstract]
[Full Text]
-
Masquelier, B., Droz, C., Dary, M., Perronne, C., Ferre, V., Spire, B., Descamps, D., Raffi, F., Brun-Vezinet, F., Chene, G., the APROCO/COPILOTE Study Group,
(2003). R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen. Antimicrob. Agents Chemother.
47: 3623-3626
[Abstract]
[Full Text]
-
Shafer, R. W.
(2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev.
15: 247-277
[Abstract]
[Full Text]
-
Beck, I. A., Mahalanabis, M., Pepper, G., Wright, A., Hamilton, S., Langston, E., Frenkel, L. M.
(2002). Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors. J. Clin. Microbiol.
40: 1413-1419
[Abstract]
[Full Text]
-
Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C.
(2001). Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrob. Agents Chemother.
45: 893-900
[Abstract]
[Full Text]
-
Vergne, L., Peeters, M., Mpoudi-Ngole, E., Bourgeois, A., Liegeois, F., Toure-Kane, C., Mboup, S., Mulanga-Kabeya, C., Saman, E., Jourdan, J., Reynes, J., Delaporte, E.
(2000). Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients. J. Clin. Microbiol.
38: 3919-3925
[Abstract]
[Full Text]